Serum and adrenal corticosterone was measured by competitive protein-binding radioassay in rats subjected to saline injection, ACTH administration or ether fumes. Groups of rats were tested at 5, 7, 9, 11, 13, 15, 20 and 25 days of age and measurement of hormone level was made either before treatment, to obtain basal values, or 15 min after treatment. Furthermore, the time-course of corticosterone release after ether was determined in 9- and 15-day-old rats. Neonatal rats responded to ether exposure, ACTH administration or saline injection with a significant rise in serum and adrenal corticosterone concentration above basal levels as early as 5 days of age. By 9 days of age, response to stress was qualitatively the same as that of the 25-day-old rat. The time course of adrenal responsiveness to ether stress was similar in 9- and 15-day-old rats, both age groups showing significant increases in hormone concentration by 15 min. These results contradict the concept of the ‘stress non-responsive period’ which was promoted by previous studies based on the nuorometric analysis of corticosterone.

No abstract

Previous studies have shown that mu (mu) and kappa (kappa) opioid antagonists inhibit suckling-induced prolactin release. Prolactin responses elicited by pup suckling or opioid administration are mediated, at least in part, by suppression of dopamine (DA) release from tuberoinfundibular dopaminergic (TIDA) neurons in the hypothalamus. We examined the effects of the mu opiate receptor antagonist, beta-funaltrexamine (beta-FNA), and the kappa opiate receptor antagonist, nor-binaltorphimine (nor-BNI) on the activity of TIDA neurons in lactating rats. TIDA neuronal activity was determined by measuring DOPA accumulation in the caudate putamen (CP) and median eminence (ME). The effects of opioid antagonist treatment were determined in pup-deprived (low circulating prolactin levels) or pup-suckled rats (high circulating prolactin levels). The accumulation of 5-hydroxytryptophan (5-HTP) in the medial preoptic area (MPOA), the anterior hypothalamus (AH) and the median eminence (ME) was quantified as an index of serotonergic activity in the same animals for comparative purposes. In vehicle treated rats, suckling caused a significant and selective decrease in DOPA accumulation in the ME. beta-FNA (5 micrograms, i.c.v.) pretreatment significantly increased DOPA accumulation in the ME of pup-deprived and pup-suckled rats. beta-FNA pretreatment also prevented the suckling-induced suppression of DOPA accumulation in the ME. In contrast to the actions of beta-FNA, pretreatment with nor-BNI (8 micrograms, i.c.v.) did not significantly affect the activity of the TIDA neurons in pup-deprived or pup-suckled rats. Suckling alone did not alter 5-HTP accumulation in any of the brain regions examined, and neither opioid antagonist had appreciable effects on 5-HTP accumulation. These results demonstrate that the EOP tonically inhibit the TIDA neurons in both pup-deprived and pup-suckled, post-partum female rats by acting through the mu, but not the kappa, opiate receptor subtype. Furthermore, the suckling-induced inhibition of TIDA neurons is also mediated through the EOP acting at mu, but not kappa opioid receptors.

No abstract

Beta-endorphin (β-END) is an inhibitory factor in the neuroendocrine control of luteinizing hormone (LH) release and thus, presumably also of hypophysiotropic luteinizing hormone-releasing hormone (LHRH) release. In order to address if the median eminence (ME) is a site of β-END action, we studied its functional role in ewes by assessing: (a) the hypothalamic distribution of β-END using immunolabeling and by comparing this distribution with our data on the localization of LHRH; (b) the ME in vivo release of LHRH and β-END during the luteal (day 12) and the follicular (day 15) phases of the estrous cycle; (c) the in vivo release of LHRH from the posterior-lateral ME, as assessed by push-pull cannula (PPC) sampling, before, during, and after infusion of increasing doses of β-END or naloxone through the PPC, during the follicular phase; and (d) the in vivo release of ME-LHRH and serum LH, before, during, and after infusion of β-END or naloxone in luteal and follicular ewes. In the ewe, β-END-containing perikarya are located in and around the arcuate nucleus. Their processes are also present in the diagonal band, medial septal nucleus, and medial and lateral hypothalamic areas, including the preoptic region and posterior ME. Perikarya containing LHRH are located in the preoptic area and project also to the ME, providing opportunities for synaptic interactions between β-END and LHRH-con-taining perikarya and processes at these levels. ME in vivo release of LHRH and β-END increase from the luteal (low LH/high progesterone, P4) to the follicular phase (high LH/ low P4). In follicular ewes, in vivo LHRH and LH release is decreased, in a dose-dependent manner, by β-END infused through the PPC probe into the posterior-lateral ME. In contrast, infusion of naloxone under similar conditions increases LHRH and LH release, also in a dose-dependent fashion. The inhibitory effect of β-END on LHRH and LH, as well as the stimulatory effect of naloxone on LHRH and LH, were only marginally apparent in luteal ewes. These results suggest that the ME is a major control site where β-END exerts its influence on hypophysiotropic LHRH release. The strength of this inhibitory effect apparently increases throughout the follicular phase, and might prevent the premature onset of the preovulatory surge of LHRH and LH.